Abstract YO16
Case summary
Thai male patient, 58 years old
He had been diagnosed essential hypertension and dyslipidemia for over 10 years (2005) and received cadaveric donor kidney transplantation on Oct 2005.
In May 2017, he presented with left hip closed fracture, in plain film of Lt hip had showed osteolytic lesion at left head and neck of femur with fracture at intertrochanter of femur.
He received bone biopsy and result showed metastatic clear cell renal cell carcinoma.
On CT chest and whole abdomen include pelvis had seen heterogeneous enhancing mass at right native kidney size 7.1 x 7.2 x 8.5 cm with synchronous lesion at transplanted kidney size 1.1 x 1.4 cm and pathological lymph nodes at internal iliac artery, no distance metastasis.
He underwent surgery to debulk tumor and hemiarthroplasty of left hip and received post-operative radiotherapy. Post-operative, he had been added everolimus 0.5 mg per day.
He starts treatment with Pazopanib since June 2007 until now and has hand foot syndrome grade I, diarrhea grade I, his blood pressure is well controlled and now he still has partial response.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract